RE:RE:RE:I have a new rabbit hole to go downI may be wrong, but the way I read the last
MD&A Theralase plans to do a
single adaptive Phase Ib/II which includes both
GBM and
NSCLC.
Once Rutherrin®’s Maximum Tolerated Dose (“MTD”) and hence Human Equivalent Dose (“HED”) limits have been determined through Good Laboratory Practices (“GLP”) toxicology studies, Theralase®, subject to the required regulatory approvals, plans to intravenously inject Rutherrin® into patients via a Phase Ib/II adaptive clinical study design, to first determine localization to various cancer cells, including Glio Blastoma Multiforme (“GBM”) and Non-Small Cell Lung Cancer (“NSCLC”) and then in an adaptive design activate Rutherrin® with radiation with the intent of safely and effectively destroying the cancer of interest. DJDawg wrote: I don't know but my hunch is that GBM is the plan for next step.
GBM is rapidly fatal with limited treatment options.
If you set up a phase 1a in Toronto you would have no trouble getting patients and the turnaround time to show benefit would be a few months (acceptable benefit for GBM would be a drop in size of tumour about 1 cm in diameter). That wouldn't be hard to prove if it works. Then you get lots of ra-ra and hype and would have an easy time rolling from there.
If you did a phase 1 in lung you would have lots and lots of competing trials for the patients to join. Slower changing cancer so not as obvious in benefit as GBM over months.
I don't know one way or other but GBM first is my guess. If they can get the money.